Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Current Leases (2021 - 2025)

Coeptis Therapeutics Holdings has reported Current Leases over the past 5 years, most recently at $18875.0 for Q4 2025.

  • Quarterly results put Current Leases at $18875.0 for Q4 2025, down 55.38% from a year ago — trailing twelve months through Dec 2025 was $18875.0 (down 55.38% YoY), and the annual figure for FY2025 was $18875.0, down 55.38%.
  • Current Leases for Q4 2025 was $18875.0 at Coeptis Therapeutics Holdings, down from $29865.0 in the prior quarter.
  • Over the last five years, Current Leases for COEPW hit a ceiling of $42305.0 in Q1 2024 and a floor of $9890.0 in Q3 2024.
  • Median Current Leases over the past 5 years was $25801.5 (2025), compared with a mean of $26765.1.
  • Peak annual rise in Current Leases hit 201.97% in 2025, while the deepest fall reached 55.38% in 2025.
  • Coeptis Therapeutics Holdings' Current Leases stood at $14724.0 in 2021, then surged by 182.65% to $41618.0 in 2022, then fell by 8.58% to $38047.0 in 2023, then grew by 11.19% to $42305.0 in 2024, then plummeted by 55.38% to $18875.0 in 2025.
  • The last three reported values for Current Leases were $18875.0 (Q4 2025), $29865.0 (Q3 2025), and $21738.0 (Q2 2025) per Business Quant data.